These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23248148)

  • 1. Nondipping and cardiovascular risk after morning renin-angiotensin blockade.
    Portaluppi F; Smolensky M; Ayala DE; Hermida RC
    Hypertension; 2013 Feb; 61(2):e15. PubMed ID: 23248148
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to nondipping and cardiovascular risk after morning renin–angiotensin blockade.
    Mancia G;
    Hypertension; 2013 Feb; 61(2):e16. PubMed ID: 23444461
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 4. [The ONTARGET trial].
    Verdecchia P; Terrosu P
    G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
    [No Abstract]   [Full Text] [Related]  

  • 5. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.
    Gosse P; Neutel JM; Schumacher H; Lacourcière Y; Williams B; Davidai G
    Blood Press Monit; 2007 Jun; 12(3):141-7. PubMed ID: 17496463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies.
    Gosse P; Schumacher H
    Hypertens Res; 2014 Feb; 37(2):151-7. PubMed ID: 24048485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.
    Schmieder RE; Delles C; Mimran A; Fauvel JP; Ruilope LM
    Diabetes Care; 2007 Jun; 30(6):1351-6. PubMed ID: 17337492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of hypertension. Also pulse pressure must be reduced].
    MMW Fortschr Med; 2003 Sep; 145(37):65. PubMed ID: 14584451
    [No Abstract]   [Full Text] [Related]  

  • 13. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 14. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of hypertension. Lasting organ protection moves into the foreground].
    MMW Fortschr Med; 2003 Nov; 145(47):62. PubMed ID: 14738040
    [No Abstract]   [Full Text] [Related]  

  • 16. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
    Mancia G; Parati G; Bilo G; Gao P; Fagard R; Redon J; Czuriga I; Polák M; Ribeiro JM; Sanchez R; Trimarco B; Verdecchia P; van Mieghem W; Teo K; Sleight P; Yusuf S
    Hypertension; 2012 Dec; 60(6):1400-6. PubMed ID: 23071122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 18. Perindopril for improving cardiovascular events.
    DiNicolantonio JJ; O'Keefe JH
    Vasc Health Risk Manag; 2014; 10():539-48. PubMed ID: 25210459
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
    Sleight P; Redon J; Verdecchia P; Mancia G; Gao P; Fagard R; Schumacher H; Weber M; Böhm M; Williams B; Pogue J; Koon T; Yusuf S;
    J Hypertens; 2009 Jul; 27(7):1360-9. PubMed ID: 19506526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Telmisartan (micardis) -- an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?].
    Chazova IE
    Ter Arkh; 2003; 75(6):89-91. PubMed ID: 12920969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.